more

Novartis (NVS)

(Delayed Data from NYSE)

$106.45 USD

-0.63 (-0.59%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $107.09 +0.64 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Research for NVS

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Hematology: Promacta/Re...		2,269	2,088	2,016	1,738	1,416
Revenues: Established Brands: Gal...		692	859	1,092	1,199	1,297
Revenues: Established Brands: Exf...		713	743	901	980	1,025
Revenues: Hematology: Kymriah: To...		508	536	587	474	278
Revenues: Hematology: Tasigna: To...		1,848	1,923	2,060	1,958	1,880
Revenues: Other Promoted Brands: ...		1,475	1,874	2,160	1,933	2,086
Revenues: Established Brands: San...		1,314	1,238	1,413	1,439	1,585
Revenues: Hematology: Jakavi: Tot...		1,720	1,561	1,595	1,339	1,114
Revenues: Established Brands: Dio...		613	652	773	1,003	1,064
Total Neuroscience [$M]		4,043	3,038	5,007	--	--
Net sales: Total Oncology [$M]	--	13,590	11,176	--	--	--
Solid Tumors: Lutathera [$M]		605	471	475	--	--
Solid Tumors: Piqray [$M]		505	373	329	--	--
Solid Tumors: Pluvicto [$M]		980	271	--	--	--
Neuroscience: Zolgensma [$M]		1,214	1,370	1,351	--	--
Hematology: Scemblix [$M]		413	149	7	--	--
Neuroscience: Aimovig [$M]		266	218	215	--	--
Cardiovascular: Leqvio [$M]		355	112	12	--	--
Total Immunology [$M]		7,798	7,287	7,205	--	--
Total Cardiovascular [$M]		6,391	4,756	3,560	--	--
Total Promoted Brands [$M]		31,822	26,257	29,754	--	--
Established Brands: Contract manu...		1,490	1,200	108	--	--
Established Brands: Other [$M]		5,427	6,113	4,257	--	--
Total Established Brand [$M]		13,618	15,949	12,241	--	--
Neuroscience: Kesimpta [$M]		2,171	1,092	372	--	--
Revenues: Net sales to third part...		45,440	42,206	51,626	48,659	47,445
Revenues: Other revenues [$M]		1,220	1,255	1,251	1,239	1,179
Revenues: Cardiovascular: Entrest...		6,035	4,644	1,836	2,497	1,726
Revenues: Immunology: Cosentyx: T...		4,980	4,788	3,548	3,995	3,551
Revenues: Immunology: Xolair: Tot...		1,463	1,365	1,428	1,251	1,173
Revenues: Immunology: Ilaris: Tot...		1,355	1,133	1,059	873	671
Revenues: Neuroscience: Gilenya: ...		925	2,013	2,787	3,003	3,223
Revenues: Solid Tumors: Tafinlar ...		1,922	1,770	1,693	1,542	1,338
Revenues: Solid Tumors: Kisqali: ...		2,080	1,231	937	687	480
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Hematology: Promacta/Re...		1,205	1,083	947	833	691
Revenues: Immunology: Cosentyx: U...		2,636	2,770	2,883	2,516	2,220
Revenues: Immunology: Cosentyx: R...		2,344	2,018	4,718	1,479	1,331
Revenues: Established Brands: Exf...		700	729	887	964	1,012
Revenues: Established Brands: San...		829	800	843	837	881
Revenues: Established Brands: San...		485	438	570	602	704
Revenues: Immunology: Ilaris: US ...		686	570	501	400	304
Revenues: Immunology: Ilaris: ROW...		669	563	558	473	367
Revenues: Established Brands: Dio...		52	55	51	124	86
Revenues: Established Brands: Dio...		561	597	722	879	978
Revenues: Solid Tumors: Kisqali: ...		1,032	472	339	318	250
Revenues: Solid Tumors: Kisqali: ...		1,048	759	598	369	230
Neuroscience: Zolgensma: US [$M]		372	434	469	--	--
Neuroscience: Zolgensma: ROW [$M]		842	936	882	--	--
Revenues: Neuroscience: Kesimpta:...	--	1,528	921	--	--	--
Revenues: Neuroscience: Kesimpta:...	--	643	171	--	--	--
Net sales: Oncology: Pluvicto: US...	--	921	--	--	--	--
Net sales: Oncology: Pluvicto: RO...	--	59	--	--	--	--
Net sales: Oncology: Lutathera: U...	--	427	--	--	--	--
Net sales: Oncology: Lutathera: R...	--	178	--	--	--	--
Net sales: Cardiovascular, renal ...	--	427	--	--	--	--
Net sales: Cardiovascular, renal ...	--	178	--	--	--	--
Net sales from continuing operati...	--	27,481	--	--	--	--
Net sales from continuing operati...	--	17,959	15,935	16,818	16,484	16,280
Net sales from continuing operati...	--	14,997	14,371	20,197	18,715	17,933
Net sales from continuing operati...	--	9,308	8,978	10,966	10,219	9,799
Net sales from continuing operati...	--	3,176	2,922	3,645	3,241	3,433
Revenues: Cardiovascular: Entrest...		3,067	2,354	1,712	1,277	925
Revenues: Cardiovascular: Entrest...		2,968	2,290	1,836	1,220	801
Revenues: Neuroscience: Gilenya: ...		359	1,153	1,427	1,562	1,736
Revenues: Neuroscience: Gilenya: ...		566	860	1,360	1,441	1,487
Revenues: Hematology: Tasigna: US...		884	877	882	859	804
Revenues: Hematology: Tasigna: RO...		964	1,046	1,178	1,099	1,076
Revenues: Solid Tumors: Tafinlar ...		791	678	606	569	481
Revenues: Solid Tumors: Tafinlar ...		1,131	1,092	1,087	973	857
Revenues: Established Brands: Exf...		13	14	14	16	13
Revenues: Hematology: Promacta/Re...		1,064	1,005	1,069	905	725

Revenue - Line of Business Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Revenues: Hematology: Promacta/Re...		569	544	520	563	576
Revenues: Established Brands: Gal...		159	150	149	153	181
Revenues: Established Brands: Exf...		174	178	192	156	187
Revenues: Hematology: Kymriah: To...		102	113	120	120	124
Revenues: Hematology: Tasigna: To...		419	446	395	446	464
Revenues: Other Promoted Brands: ...		245	275	314	301	363
Revenues: Established Brands: San...		305	313	355	316	338
Revenues: Hematology: Jakavi: Tot...		500	471	478	444	427
Revenues: Established Brands: Dio...		150	160	140	147	153
Total Neuroscience [$M]		1,225	1,225	1,009	1,102	1,034
Net sales: Total Oncology [$M]		3,824	3,640	3,344	3,508	3,284
Solid Tumors: Lutathera [$M]		190	175	169	147	159
Solid Tumors: Piqray [$M]		111	120	109	131	128
Solid Tumors: Pluvicto [$M]		386	345	310	273	256
Neuroscience: Zolgensma [$M]		308	349	295	286	308
Hematology: Scemblix [$M]		182	164	136	125	106
Neuroscience: Aimovig [$M]		79	77	76	69	69
Cardiovascular: Leqvio [$M]		198	182	151	123	90
Total Immunology [$M]		2,483	2,322	2,081	2,057	2,033
Total Cardiovascular [$M]		2,063	2,080	2,030	1,759	1,575
Total Promoted Brands [$M]		--	9,267	8,464	8,426	8,448
Established Brands: Contract manu...		279	271	279	302	471
Established Brands: Other [$M]		1,786	1,760	1,761	1,243	1,893
Total Established Brand [$M]		3,228	3,245	3,365	2,997	3,856
Neuroscience: Kesimpta [$M]		838	799	637	641	657
Net sales: Oncology: Fabhalta [$M...		44	22	6	--	--
Revenues: Net sales to third part...		12,823	12,512	11,829	11,423	11,782
Revenues: Other revenues [$M]		349	360	291	353	310
Revenues: Cardiovascular: Entrest...		1,865	1,898	1,879	1,635	1,485
Revenues: Immunology: Cosentyx: T...		1,693	1,526	1,326	1,303	1,329
Revenues: Immunology: Xolair: Tot...		418	427	399	378	369
Revenues: Immunology: Ilaris: Tot...		372	368	356	376	335
Revenues: Neuroscience: Gilenya: ...		130	138	175	154	270
Revenues: Solid Tumors: Tafinlar ...		534	523	474	486	482
Revenues: Solid Tumors: Kisqali: ...		787	717	627	610	562
Revenue - Geographic Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Revenues: Hematology: Promacta/Re...		306	283	266	301	314
Revenues: Immunology: Cosentyx: U...		993	868	661	741	717
Revenues: Immunology: Cosentyx: R...		700	658	665	562	612
Revenues: Established Brands: Exf...		173	177	188	154	184
Revenues: Established Brands: San...		187	187	239	199	218
Revenues: Established Brands: San...		118	126	116	117	120
Revenues: Immunology: Ilaris: US ...		205	194	166	200	182
Revenues: Immunology: Ilaris: ROW...		167	174	190	176	153
Revenues: Established Brands: Dio...		6	6	9	14	11
Revenues: Established Brands: Dio...		144	154	131	133	142
Revenues: Solid Tumors: Kisqali: ...		441	375	313	332	294
Revenues: Solid Tumors: Kisqali: ...		346	342	314	278	268
Neuroscience: Zolgensma: US [$M]		101	134	104	90	89
Neuroscience: Zolgensma: ROW [$M]		207	215	191	196	219
Revenues: Neuroscience: Kesimpta:...		571	555	415	453	407
Revenues: Neuroscience: Kesimpta:...		267	244	222	188	250
Net sales: Oncology: Pluvicto: US...		301	295	281	--	238
Net sales: Oncology: Pluvicto: RO...		85	50	29	--	18
Net sales: Oncology: Lutathera: U...		134	124	117	--	114
Net sales: Oncology: Lutathera: R...		56	51	52	--	45
Net sales: Cardiovascular, renal ...		101	94	74	--	--
Net sales: Cardiovascular, renal ...		97	88	77	--	--
Net sales from continuing operati...		7,413	7,366	7,241	--	7,134
Net sales from continuing operati...		5,410	5,146	4,588	4,763	4,648
Net sales from continuing operati...		3,964	3,867	3,764	3,716	3,930
Net sales from continuing operati...		2,534	2,594	2,580	2,231	2,349
Net sales from continuing operati...		915	905	897	713	855
Revenues: Cardiovascular: Entrest...		912	947	948	880	728
Revenues: Cardiovascular: Entrest...		953	951	931	755	757
Revenues: Neuroscience: Gilenya: ...		--	30	52	55	120
Revenues: Neuroscience: Gilenya: ...		--	108	123	99	150
Revenues: Hematology: Tasigna: US...		226	230	174	220	221
Revenues: Hematology: Tasigna: RO...		193	216	221	226	243
Revenues: Solid Tumors: Tafinlar ...		227	202	184	200	201
Revenues: Solid Tumors: Tafinlar ...		307	321	290	286	281
Revenues: Established Brands: Exf...		1	1	4	2	3
Revenues: Hematology: Promacta/Re...		263	261	254	262	262

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators